Advisors Asset Management Inc. Has $346000 Holdings in Novo Nordisk A/S (NVO)

Cornelia Mascio
Dicembre 8, 2017

"The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.new TradingView.widget ({ "height": "400, "width": "625, "symbol": "NVO", "interval": "D", "timezone": "Etc/UTC", "theme": "White", "style": "1", "locale": "en", "toolbar_bg": "#f1f3f6", "enable_publishing": "false, "hideideas": "true, "referral_id": "2588"}); Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with our FREE daily email newsletter. Zacks Investment Research raised Novo Nordisk A/S from a "hold" rating to a "buy" rating and set a $55.00 price objective for the company in a report on Tuesday, October 10th. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/07/cypress-asset-management-inc-tx-invests-334000-in-novo-nordisk-as-nvo-stock.html. The stock has "Buy" rating by UBS on Tuesday, December 6.

A number of other hedge funds and other institutional investors also recently modified their holdings of NVO.

Analysts await Novo Nordisk A/S (NYSE:NVO) to report earnings on February, 1. After $0.62 actual earnings per share reported by Novo Nordisk A/S for the previous quarter, Wall Street now forecasts -9.68 % negative EPS growth. BB&T Investment Services Inc. boosted its position in shares of Novo Nordisk A/S by 48.8% during the third quarter. Proficio Capital Partners LLC now owns 2,622 shares of the company's stock valued at $111,000 after purchasing an additional 150 shares during the period. Willingdon Wealth Management now owns 45,316 shares of the company's stock valued at $1,944,000 after acquiring an additional 1,325 shares during the last quarter.

Envestnet Asset Management Inc, which manages about $60.39 billion and $36.17 billion US Long portfolio, decreased its stake in Select Sector Spdr Tr (XLU) by 90,594 shares to 2.12 million shares, valued at $109.92M in 2017Q2, according to the filing. Company insiders own 0.07% of the company's stock.

Novo Nordisk A/S (NVO) traded up $1.37 during trading on Thursday, reaching $52.07. The stock had a trading volume of 606,717 shares, compared to its average volume of 2,098,421.

In other news, insider Eric S. Sprott bought 50,000 shares of the stock in a transaction dated Wednesday, November 8th. BidaskClub raised shares of Novo Nordisk A/S from a "sell" rating to a "hold" rating in a research report on Saturday, August 12th. The firm has a market cap of $129,285.00, a P/E ratio of 22.14, a PEG ratio of 3.01 and a beta of 0.63. The shares were purchased at an average cost of $8.34 per share, with a total value of $417,000.00. Finally, Bank of America raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a report on Wednesday, September 6th. Novo Nordisk A/S has a 1 year low of $32.83 and a 1 year high of $52.45. BNP Paribas lowered shares of Novo Nordisk A/S from an "outperform" rating to a "neutral" rating in a report on Monday, September 25th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company's stock. The stock has a consensus rating of "Hold" and a consensus target price of $55.00. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of USA and global copyright and trademark law. If you are reading this report on another site, it was stolen and republished in violation of United States & worldwide trademark & copyright law.

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates in two divisions, Diabetes and Obesity Care, and Biopharmaceuticals.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE